Veracyte, Inc. VCYT
At Veracyte, we believe that exceptional cancer care begins with exceptional diagnostics. 10-K, Item 1
- Headquarters
- South San Francisco, CA
- CEO
- Marc Stapley
- Next results
- around Jan 11, 2027
Where each dollar of revenue went, FY2025
Revenue of $517.1M through the costs to a net profit of $66.4M · income statement of the 10-K
VCYT among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
11 new risk paragraphs. 10-K filed Feb 26, 2026 against Feb 28, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 11 checks found nothing to note
-
Receivables -4.0% ($46.5M to $44.7M) vs revenue +16.0% ($445.8M to $517.1M), -20.0 pts apart
-
Cash from operations $136.3M vs net income $66.4M (FY ending Dec 31, 2025)
-
Inventory -5.5% ($21.8M to $20.5M) vs revenue +16.0% ($445.8M to $517.1M), -21.5 pts apart
8 more checks with nothing to note
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Revenue from testing
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
11 paragraphs in Risk Factors that were not in the 10-K filed Feb 28, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
IVDR’s transitional timelines regarding compliance deadlines according to IVD risk classifications as well as designations of Swiss Authorized Representatives.
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
Furthermore, the C2i Acquisition included acquiring personal data that may originate from, be processed in, or be transferred to and from, Israel, the EU and other jurisdictions. Our ability to process, use and transfer such personal data may
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $296.5M | $361.1M | $445.8M | $517.1M |
| Net income | −$36.6M | −$74.4M | $24.1M | $66.4M |
| Operating cash flow | $7.5M | $44.2M | $75.1M | $136.3M |
| Free cash flow | −$1.0M | $34.3M | $63.8M | $126.6M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$517.1M ▲ 16.0% in FY2025$66.4M ▲ 174.9% in FY2025$126.6M ▲ 98.5% in FY2025
Recent filings
5 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 5, 2026Phil Febbo (Chief Scientific Officer and Chief Medical Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 87,844 shares, runs to Nov 26, 2027
-
10-QNov 5, 2026Quarterly report (10-Q) period ended Sep 30, 2026
-
8-KNov 4, 2026Quarterly results, Other events 8-K items 2.02, 8.01
-
Planned saleOct 27, 2026JENS HOLSTEIN (Director) gave notice of a planned sale of 7,500 shares worth about $375K Form 144, approximate sale date Oct 27, 2026, under a 10b5-1 plan adopted Jun 12, 2026
-
Planned saleOct 27, 2026KARIN EASTHAM (Director) gave notice of a planned sale of 14,850 shares worth about $716K Form 144, approximate sale date Oct 27, 2026, under a 10b5-1 plan adopted May 28, 2026
About the company
Veracyte, Inc., South San Francisco, CA · from the 10-K filed Feb 26, 2026
At Veracyte, we believe that exceptional cancer care begins with exceptional diagnostics. We are a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and predictive treatment decisions. Insights from these tests help patients avoid unnecessary procedures and interventions and accelerate time to appropriate treatment, thereby improving outcomes for patients across our global markets.
- Headquarters
- South San Francisco, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 28, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VCYT/export.csv") into a cell.